SOURCE: Barrier Therapeutics, Inc.

May 02, 2005 18:30 ET

Barrier Therapeutics Announces Launch of U.S. Sales Organization

Company Engages Ventiv Health to Supplement Its Commercialization Efforts

PRINCETON, NJ -- (MARKET WIRE) -- May 2, 2005 -- Barrier Therapeutics, Inc. (NASDAQ: BTRX), a pharmaceutical company developing and commercializing products in the field of dermatology, today announced plans for the creation of its U.S. sales organization. Barrier previously announced the hiring of three senior executives for its commercial organization, including Stephen Miller, Vice President of Sales. Barrier today signed an agreement with Ventiv Health, Inc. (NASDAQ: VTIV), a leading provider of sales, marketing and compliance solutions to pharmaceutical and biotechnology companies with significant experience in specialty pharmaceutical sales solutions and dermatology products.

Over the next three months Barrier plans to build a field sales organization in the United States that will include six Barrier Regional Managers and approximately 60 sales representatives, comprised of up to 20 who will be Barrier employees and at least 40 who will be Ventiv employees. Barrier has already recruited three experienced Regional Managers who will lead the hiring of the first 30 sales representatives. The Company plans to expand the sales organization to a full complement of 60 sales representatives upon approval of Zimycan™ by the U.S. FDA. In conjunction with the launch of its own sales organization, Barrier signed an agreement with Ventiv for supplemental sales and marketing services. Under the agreement, Ventiv will provide a number of complementary services including sales information systems, fleet management, training and logistics as well as recruiting support for the Barrier field force and the Ventiv sales representatives.

"We are excited about the initiation of our U.S. sales organization and our partnership with Ventiv," said Al Altomari, Chief Commercial Officer of Barrier Therapeutics. "During 2005 Barrier will continue its transition into a commercial organization. Initially our sales organization will focus its efforts on Solagé® (mequinol 2%, tretinoin 0.01%) Topical Solution which we acquired earlier this year. We are also continuing to prepare for the sales force expansion and the launch of Zimycan, pending FDA approval later this year. Our current plan is to have all 60 sales representatives be Barrier employees by next summer."

About Barrier Therapeutics, Inc.

Barrier Therapeutics, Inc. is a pharmaceutical company focused on the discovery, development and commercialization of pharmaceutical products in the field of dermatology. The Company currently markets Solagé® in the U.S. and Canada for the treatment of solar lentigines, a common condition also known as "age spots" or "liver spots." Barrier has eight product candidates in various stages of clinical development. The four most advanced product candidates include one for the treatment of diaper dermatitis complicated by candidiasis, which is in registration and three products, which are in or entering Phase 3 clinical trials for the treatment of seborrheic dermatitis, fungal infections, including vaginal candidiasis, and congenital ichthyosis. Barrier has product candidates in earlier stages of clinical development for the treatment of acne, psoriasis and fungal infections. The Company is headquartered in Princeton, New Jersey, and has wholly owned subsidiaries in Geel, Belgium and Ontario, Canada. Web site: http://www.barriertherapeutics.com.

About Ventiv Health

Ventiv Health, Inc. (NASDAQ: VTIV) is the leading provider of late-stage clinical, sales, marketing and compliance solutions to pharmaceutical and biotech companies. Ventiv is a multi-disciplinary company with a singular focus on providing excellence in customized solutions across the full spectrum of services combining both integrated and independent programs. Ventiv's approximately 4,000 employees support over 75 client organizations, including the world's Top 20 pharmaceuticals companies as well as emerging and specialty biotech leaders. For more information on Ventiv Health, visit http://www.ventiv.com

Quarterly Financial Results Conference Call & Webcast Information

Barrier's senior management will host a conference call on, Tuesday, May 3, 2005 at 5:00 p.m. New York time to review 2005 first quarter financial results, discuss operations, and provide guidance on Barrier's 2005 business outlook. Live audio of the conference call will be available to investors, members of the news media and the general public by dialing 1-800-322-0079 (in the United States) or 1-973-409-9258 (internationally). To access the call by live webcast, please visit the Investor Relations section of our website.

Safe Harbor Statement

In addition to historical facts or statements of current condition, this press release contains forward-looking statements within the meaning of the "Safe Harbor" provisions of The Private Securities Litigation Reform Act of 1995, including statements regarding the timing of regulatory action and the anticipated launch of Zimycan and launching a sales force. Forward-looking statements provide Barrier's current expectations or forecasts of future events. Barrier's performance and financial results could differ materially from those reflected in these forward-looking statements due to the decisions of regulatory authorities, our ability to execute our clinical and commercial strategy, the results of our clinical trials, general financial, economic, regulatory and political conditions affecting the biotechnology and pharmaceutical industries generally, and due to Barrier's further analysis of clinical results and strategic decisions regarding its pipeline. For a discussion of these and other risks and uncertainties that may effect the forward-looking statements please see the risk factors in our Annual Report on Form 10K, which is on file with the Securities and Exchange Commission. Given these risks and uncertainties, any or all of these forward-looking statements may prove to be incorrect. Barrier undertakes no obligation to update publicly any forward-looking statement.

Contact Information

  • Contact:
    Barrier Therapeutics, Inc.
    Anne M. VanLent
    609-945-1202

    Noonan Russo
    Jane Petrino
    212-845-4274